Session » Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA
- 4:00PM-5:30PM
-
Abstract Number: 1691
16-Week Results from FOREMOST, a Placebo-Controlled Study Involving Oligoarticular Psoriatic Arthritis Treated with Apremilast
- 4:00PM-5:30PM
-
Abstract Number: 1690
Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study
- 4:00PM-5:30PM
-
Abstract Number: 1689
Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy
- 4:00PM-5:30PM
-
Abstract Number: 1692
Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
- 4:00PM-5:30PM
-
Abstract Number: 1688
Izokibep Demonstrates Major Disease Control on ACR70, PASI100 and Enthesitis Resolution in Patients with Active Psoriatic Arthritis Treated Through 46 Weeks
- 4:00PM-5:30PM
-
Abstract Number: 1687
Sex of the Patient Affects Response to Advanced Therapies in Psoriatic Arthritis: Meta-analysis of Data from Randomized Controlled Trials